Ciclacillin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Bioactive by-products |
| Catalog number | BBF-00641 |
| CAS | 3485-14-1 |
| Molecular Weight | 341.42 |
| Molecular Formula | C15H23N3O4S |
| Purity | 98% |
Online Inquiry
Description
Ciclacillin is produced by the strain of Semi-synthetic broad-spectrum penicillin. The antibacterial activity of cyclociline against 101 strains of Escherichia coli, 50 strains of Proteus and 59 strains of Staphylococcus aureus was lower than that of ampicillin and carboxpicillin. The blood concentration is higher than ampicillin, but excretion is fast.
Specification
| Synonyms | Aminocyclohexylpenicillin; Calthor; Ciclacillin; Ciclacillum; Citosarin; Cyclapen; (Aminocyclohexyl)penicillin; Syngacillin; Ultracillin; Vastcillin; Vatracin; Vipicil; Wy 4508; Wyvital; (1-Aminocyclohexyl)penicillin; 6-(1-Aminocyclohexanecarboxamido)penicillanic Acid; [2S-(2α,5α,6β)]-6-[[(1-Aminocyclohexyl)carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid |
| Storage | Store at -20°C |
| IUPAC Name | (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| Canonical SMILES | CC1(C(N2C(S1)C(C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C |
| InChI | InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1 |
| InChI Key | HGBLNBBNRORJKI-WCABBAIRSA-N |
Properties
| Appearance | White to Light Yellow Crystallines |
| Antibiotic Activity Spectrum | fungi |
| Boiling Point | 649.6±55.0°C at 760 mmHg |
| Melting Point | 156-158°C (dec.) |
| Density | 1.400±0.10 g/cm3 |
| Solubility | Soluble in Water (32 g/L at 25 °C) |
Reference Reading
1. Penetration of ciclacillin into bronchial secretions
P Dougan, M Bone, J Symonds Chemioterapia . 1986 Apr;5(2):105-8.
The penetration of ciclacillin into bronchial secretions was investigated in 105 patients undergoing bronchoscopy after a single oral dose of 500 mg ciclacillin. Comparison was made with 26 patients who received 500 mg ampicillin by mouth. Over a 6 to 8 hour period, ciclacillin achieved significantly higher levels in bronchial secretions but no statistically significant difference between serum ampicillin and ciclacillin levels was detected.
2. Gender differences in kidney function
Gerhard Burckhardt, Christoph Wanke, Abdul R Asif, Wolfgang E Budach, Ivan Sabolić, Andrew Bahn Pflugers Arch . 2007 Dec;455(3):397-429. doi: 10.1007/s00424-007-0308-1.
Sex hormones influence the development of female (F) and male (M) specific traits and primarily affect the structure and function of gender-specific organs. Recent studies also indicated their important roles in regulating structure and/or function of nearly every tissue and organ in the mammalian body, including the kidneys, causing gender differences in a variety of characteristics. Clinical observations in humans and studies in experimental animals in vivo and in models in vitro have shown that renal structure and functions under various physiological, pharmacological, and toxicological conditions are different in M and F, and that these differences may be related to the sex-hormone-regulated expression and action of transporters in the apical and basolateral membrane of nephron epithelial cells. In this review we have collected published data on gender differences in renal functions, transporters and other related parameters, and present our own microarray data on messenger RNA expression for various transporters in the kidney cortex of M and F rats. With these data we would like to emphasize the importance of sex hormones in regulation of a variety of renal transport functions and to initiate further studies of gender-related differences in kidney structure and functions, which would enable us to better understand occurrence and development of various renal diseases, pharmacotherapy, and drug-induced nephrotoxicity in humans and animals.
3. [Ciclacillin therapy for diseases of the urinary tract]
H Knothe, G Dathe MMW Munch Med Wochenschr . 1975 Apr 4;117(14):587-90.
In our own controlled bacteriological investigations, ciclacillin showed a good effect in urological infections at a daily dosage of 3 g for 10 days. The efficacy is comparable to that of ampicillin and corresponds to that of the double blind trials bescribed in the literature. The specially good tolerance is worthy of note.
Recommended Products
| BBF-03819 | Spinosyn A | Inquiry |
| BBF-03516 | (±)-Naringenin | Inquiry |
| BBF-05886 | Notoginsenoside R1 | Inquiry |
| BBF-05781 | Emodepside | Inquiry |
| BBF-03827 | Polymyxin B sulphate | Inquiry |
| BBF-02577 | Pneumocandin C0 | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
